Abstract
目的建立敲除RNA腺苷脱氨酶1(ADAR1)的小鼠MLL-AF9融合基因急性髓系白血病（AML）模型，初步探讨ADAR1对AML发病的影响。方法采用免疫磁珠法富集介导雌激素受体-重组酶Cre (ER-Cre)的ADAR1lox/lox及其对照ADAR1lox/lox小鼠骨髓Lineage−（Lin−）细胞，用携带MSCVMLL/AF9-IRES-GFP的逆转录病毒感染上述Lin−细胞，流式细胞术检测感染效率，移植相同数量细胞至致死剂量和半致死剂量照射受体小鼠中，建立MLL-AF9诱导的AML模型。移植48 h后诱导ADAR1敲除，体内实验分为实验组（ER-Cre;ADAR1lox/lox＋他莫昔芬）和对照组(①ER-Cre;ADAR1lox/lox +空载体、②ADAR1lox/lox+他莫昔芬、③ADAR1lox/lox＋空载体)，第10、15、20天分别检测小鼠外周血GFP+细胞比例，观察各组小鼠的存活情况。体外实验分组同上，将他莫昔芬改为4-羟基他莫昔芬，观察各组AML细胞并检测其凋亡情况。结果成功建立敲除ADAR1的MLL-AF9融合基因AML小鼠模型。与对照组比较，体内实验中实验组AML小鼠在各时间点外周血GFP+细胞比例均降低，存活时间明显延长，差异均有统计学意义(P值均<0.05)；体外实验中实验组细胞总数、GFP+细胞比例均降低，Annexin Ⅴ+7-AAD+和Annexin Ⅴ+细胞比例均升高，差异均有统计学意义(P值均<0.05)。结论敲除ADAR1可减缓AML的发病，增加AML细胞凋亡。ADAR1在MLL-AF9诱导的AML发生和维持过程中起关键作用。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
